Cytokinetics to Unveil ACACIA-HCM nHCM Results Tomorrow

What happened

Cytokinetics announced it will report topline results from the pivotal Phase 3 ACACIA-HCM trial of aficamten in non-obstructive hypertrophic cardiomyopathy on May 5, 2026. This readout is a critical binary catalyst that could either validate a second major indication for aficamten or collapse the multi-indication platform narrative. The DeepValue master report had already flagged that ACACIA failure is a key thesis breaker, while success would support a broader cardiomyopathy franchise. However, even with positive data, the company faces an uphill battle against entrenched Camzyos, a leveraged balance sheet, and no commercial track record. Investors should brace for significant volatility as the market prices in this binary event.

Implication

The ACACIA-HCM result will be decisive for Cytokinetics' valuation over the next 12-18 months. A positive outcome could open up a large nHCM market and strengthen the platform story, but the stock already trades near $63 with aggressive assumptions baked in. A negative readout would likely trigger a sharp sell-off and force a dilutive recapitalization. Given the risk-reward asymmetry skewed to downside per the DeepValue analysis, investors should de-risk positions or wait for results before re-evaluating. Even if successful, Myqorzo still needs to prove commercial execution against a dominant competitor, so tempered expectations are warranted.

Thesis delta

The thesis remains anchored to the ACACIA outcome; with results imminent, the probability distribution is about to resolve. We maintain our bearish bias given crowded bullish positioning and the high bar for success. A positive readout could temporarily lift the stock but would not change the fundamental concerns around launch execution and balance sheet leverage.